Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03631667 · ClinicalTrials.gov registry record · Early Phase 1
Ultralow Dose PAH Binary Mixture Study
A Early Phase 1 study of Environmental Exposure, sponsored by Oregon State University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT03631667: Completed Early Phase 1 study of Environmental Exposure, sponsored by Oregon State University.
NCT03631667 is a Early Phase 1 study of Environmental Exposure that has completed, run by Oregon State University. The registered enrollment target is 8 participants, below the 290-participant average among 13 other Environmental Exposure trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03631667, a Early Phase 1 study of Environmental Exposure, has completed, sponsored by Oregon State University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation of the pharmacokinetics for \[14C\]-benzo\[a\]pyrene (\[14C\]-BaP) and metabolites in plasma and urine over 48 hours following a 50 ng dose (5.4 nCi) alone or with 1250 ng phenanthrene.
Primary Outcome
Determination of highest concentration of 14C-BaP in plasma. Blood samples collected at 0 (baseline), 0.25, 0.5, 1, 2, 3, 4, 8, 24, and 48 hour after dosing. All time points were used to determine Cmax.
Conditions Studied
Interventions
- DRUG [14C]-benzo[a]pyrene
- DRUG [14C]-benzo[a]pyrene plus phenanthrene
Study Locations (1)
Oregon
- Oregon State University - Corvallis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2024-02-01 |
| Phase | Early Phase 1 |
What the finished NCT03631667 record still lists
NCT03631667 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 290-participant average among 13 other Environmental Exposure trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Environmental Exposure appearing as the primary indexed condition, and to 2 interventions - of which [14C]-benzo[a]pyrene is the first listed.
NCT03631667 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT03631667 about?
NCT03631667 is a clinical study titled "Ultralow Dose PAH Binary Mixture Study". Evaluation of the pharmacokinetics for \[14C\]-benzo\[a\]pyrene (\[14C\]-BaP) and metabolites in plasma and urine over 48 hours following a 50 ng dose (5.4 nCi) alone or with 1250 ng phenanthrene.
What is the current status of trial NCT03631667?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2018-10-01. Estimated completion is 2024-02-01.
What conditions does trial NCT03631667 study?
This clinical trial studies the following conditions: Environmental Exposure.
What interventions are being tested in trial NCT03631667?
The interventions under investigation include: [14C]-benzo[a]pyrene (DRUG), [14C]-benzo[a]pyrene plus phenanthrene (DRUG).
Who is sponsoring clinical trial NCT03631667?
This trial is sponsored by Oregon State University, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03631667 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Environmental Exposure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03631667's enrollment target sits among peer trials
8 13th of 13 the lowest of 13 other Environmental Exposure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Environmental Exposure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Benzo[a]Pyrene Ultralow Dose-Response Study
COMPLETED · Early Phase 1
-
Assessing and Addressing Community Exposures to Environmental Contaminants
RECRUITING · NA
-
Childhood Activities Nutrition and Development Oversight
RECRUITING · NA
-
Developmental Impacts of Microplastics Exposure in Early Life
RECRUITING
-
Table-Top Water Pitcher to Reduce Arsenic Exposure Among Well Users in New Hampshire
RECRUITING · NA
-
A Personalized Biomonitoring and Report-back Intervention to Reduce Exposure to Endocrine Disrupting Chemicals
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI